vs
ImmunityBio, Inc.（IBRX）与REDWOOD TRUST INC（RWT）财务数据对比。点击上方公司名可切换其他公司
ImmunityBio, Inc.的季度营收约是REDWOOD TRUST INC的1.5倍（$38.3M vs $25.9M），REDWOOD TRUST INC净利率更高（77.2% vs -161.8%，领先239.0%），ImmunityBio, Inc.同比增速更快（407.0% vs -6.1%）
ImmunityBio, Inc.是一家处于临床阶段的生物技术企业，专注开发针对多种癌症及传染性疾病的下一代免疫疗法与候选疫苗，核心研发方向涵盖细胞疗法、抗体药物及靶向疫苗平台，主要运营市场位于美国。
Redwood Trust Inc是总部位于美国的专业房地产投资信托公司，主营住宅与商业抵押贷款、抵押贷款支持证券及房地产信贷类资产的投资管理，核心业务覆盖住宅抵押贷款发放、商业地产信贷和投资服务，客户以机构投资者和房地产市场参与者为主。
IBRX vs RWT — 直观对比
营收规模更大
IBRX
是对方的1.5倍
$25.9M
营收增速更快
IBRX
高出413.0%
-6.1%
净利率更高
RWT
高出239.0%
-161.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $38.3M | $25.9M |
| 净利润 | $-61.9M | $20.0M |
| 毛利率 | 99.0% | — |
| 营业利润率 | -169.0% | — |
| 净利率 | -161.8% | 77.2% |
| 营收同比 | 407.0% | -6.1% |
| 净利润同比 | -4.7% | 402.6% |
| 每股收益（稀释后） | $-0.06 | $0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IBRXRWT
| Q4 25 | $38.3M | $25.9M | ||
| Q3 25 | $32.1M | $15.0M | ||
| Q2 25 | $26.4M | $13.8M | ||
| Q1 25 | $16.5M | $27.9M | ||
| Q4 24 | $7.6M | $27.6M | ||
| Q3 24 | $6.1M | $25.5M | ||
| Q2 24 | — | $67.4M | ||
| Q1 24 | — | $74.5M |
净利润IBRXRWT
| Q4 25 | $-61.9M | $20.0M | ||
| Q3 25 | $-67.3M | $-7.7M | ||
| Q2 25 | $-92.6M | $-98.5M | ||
| Q1 25 | $-129.6M | $16.1M | ||
| Q4 24 | $-59.2M | $-6.6M | ||
| Q3 24 | $-85.7M | $14.8M | ||
| Q2 24 | — | $15.5M | ||
| Q1 24 | — | $30.3M |
毛利率IBRXRWT
| Q4 25 | 99.0% | — | ||
| Q3 25 | 99.4% | — | ||
| Q2 25 | 99.5% | — | ||
| Q1 25 | 99.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率IBRXRWT
| Q4 25 | -169.0% | — | ||
| Q3 25 | -173.5% | -9.0% | ||
| Q2 25 | -269.8% | -679.0% | ||
| Q1 25 | -390.1% | 80.2% | ||
| Q4 24 | -919.0% | -1.3% | ||
| Q3 24 | -1314.3% | 86.1% | ||
| Q2 24 | — | 30.3% | ||
| Q1 24 | — | 41.3% |
净利率IBRXRWT
| Q4 25 | -161.8% | 77.2% | ||
| Q3 25 | -209.8% | -51.4% | ||
| Q2 25 | -350.3% | -712.0% | ||
| Q1 25 | -784.9% | 57.8% | ||
| Q4 24 | -783.4% | -24.0% | ||
| Q3 24 | -1404.0% | 58.1% | ||
| Q2 24 | — | 23.0% | ||
| Q1 24 | — | 40.6% |
每股收益（稀释后）IBRXRWT
| Q4 25 | $-0.06 | $0.11 | ||
| Q3 25 | $-0.07 | $-0.08 | ||
| Q2 25 | $-0.10 | $-0.76 | ||
| Q1 25 | $-0.15 | $0.10 | ||
| Q4 24 | $-0.08 | $-0.08 | ||
| Q3 24 | $-0.14 | $0.09 | ||
| Q2 24 | — | $0.10 | ||
| Q1 24 | — | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $242.8M | $255.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-500.5M | $982.6M |
| 总资产 | $501.9M | $23.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资IBRXRWT
| Q4 25 | $242.8M | $255.7M | ||
| Q3 25 | $257.8M | $226.3M | ||
| Q2 25 | $153.7M | $302.0M | ||
| Q1 25 | $61.6M | $259.9M | ||
| Q4 24 | $149.8M | $245.2M | ||
| Q3 24 | $130.4M | $253.7M | ||
| Q2 24 | — | $275.6M | ||
| Q1 24 | — | $275.4M |
总债务IBRXRWT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $1.7B |
股东权益IBRXRWT
| Q4 25 | $-500.5M | $982.6M | ||
| Q3 25 | $-524.3M | $999.0M | ||
| Q2 25 | $-570.7M | $1.1B | ||
| Q1 25 | $-591.4M | $1.2B | ||
| Q4 24 | $-489.1M | $1.2B | ||
| Q3 24 | $-745.1M | $1.2B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.2B |
总资产IBRXRWT
| Q4 25 | $501.9M | $23.7B | ||
| Q3 25 | $519.0M | $22.6B | ||
| Q2 25 | $402.1M | $21.3B | ||
| Q1 25 | $303.8M | $19.9B | ||
| Q4 24 | $382.9M | $18.3B | ||
| Q3 24 | $364.6M | $18.4B | ||
| Q2 24 | — | $16.5B | ||
| Q1 24 | — | $15.1B |
负债/权益比IBRXRWT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.39× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-70.4M | $-10.1B |
| 自由现金流经营现金流 - 资本支出 | $-71.3M | — |
| 自由现金流率自由现金流/营收 | -186.2% | — |
| 资本支出强度资本支出/营收 | 2.4% | — |
| 现金转化率经营现金流/净利润 | — | -504.15× |
| 过去12个月自由现金流最近4个季度 | $-308.8M | — |
8季度趋势，按日历期对齐
经营现金流IBRXRWT
| Q4 25 | $-70.4M | $-10.1B | ||
| Q3 25 | $-68.9M | $-2.7B | ||
| Q2 25 | $-79.7M | $-2.1B | ||
| Q1 25 | $-85.9M | $-2.0B | ||
| Q4 24 | $-85.1M | $-5.9B | ||
| Q3 24 | $-98.8M | $-2.1B | ||
| Q2 24 | — | $-2.0B | ||
| Q1 24 | — | $-954.2M |
自由现金流IBRXRWT
| Q4 25 | $-71.3M | — | ||
| Q3 25 | $-69.6M | — | ||
| Q2 25 | $-80.8M | — | ||
| Q1 25 | $-87.0M | — | ||
| Q4 24 | $-87.3M | — | ||
| Q3 24 | $-101.6M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率IBRXRWT
| Q4 25 | -186.2% | — | ||
| Q3 25 | -217.2% | — | ||
| Q2 25 | -305.9% | — | ||
| Q1 25 | -526.9% | — | ||
| Q4 24 | -1155.4% | — | ||
| Q3 24 | -1663.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度IBRXRWT
| Q4 25 | 2.4% | — | ||
| Q3 25 | 2.3% | — | ||
| Q2 25 | 4.1% | — | ||
| Q1 25 | 6.8% | — | ||
| Q4 24 | 28.0% | — | ||
| Q3 24 | 45.7% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金转化率IBRXRWT
| Q4 25 | — | -504.15× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -120.92× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -140.86× | ||
| Q2 24 | — | -126.56× | ||
| Q1 24 | — | -31.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
